Long-acting injectable (LAI) formulations represent a transformative approach in pharmaceutical therapeutics, enabling sustained drug delivery over extended periods ranging from weeks to months following a single administration. These systems address critical limitations of conventional dosage forms including poor patient adherence, frequent dosing requirements, and suboptimal pharmacokinetic profiles. However, LAI development faces substantial pharmaceutical challenges encompassing drug solubility and loading limitations, physicochemical and biological stability concerns, excipient biocompatibility and immunogenicity issues, complex manufacturing and scalability requirements, and rigorous regulatory pathways. This review comprehensively examines the pharmaceutical obstacles encountered in LAI formulation development and strategies to overcome these challenges. Key approaches include utilization of polymeric and lipid-based carrier systems, rational engineering of microspheres and nanoparticles, optimization of controlled-release kinetics through depot design, targeted delivery strategies, and judicious excipient selection. Clinical applications span chronic conditions including diabetes, HIV infection, psychiatric disorders, oncology, and hormonal therapies, with numerous products achieving regulatory approval and commercial success. Future directions incorporate smart stimuli-responsive systems, personalized injectable formulations, integration with precision medicine paradigms, and digital therapeutic platforms. Addressing formulation and translational challenges in LAI systems will enhance patient adherence, therapeutic outcomes, and healthcare economics while expanding treatment options for diverse clinical conditions.